Study Objective: Our hypothesis is that systemic lidocaine can significantly reduce chronic pain associated with fibromyalgia. A secondary goal of the study is to determine if other patient demographics can affect the response to IV lidocaine.
Design: Retrospective chart review
Setting: Outpatient pain clinic
Patients: 55 patients being treated for fibromyalgia by lidocaine infusion Interventions: Intravenous infusion of lidocaine 5mg/kg over 1 hour Measurements: Two-tailed paired t-tests (α=0.05) were performed to test for significant change from pre- to post-infusion in BPI, PI, and VAS scores. Smoking status and race classification were also identified.
Main Results: Mean BPI score decreased from 83.2±16.5 to 73.7±21.6 after infusion of 4 to 5 mg/ kg of lidocaine in 500 ml 5% dextrose (p-value<0.0001). Mean VAS decreased from 7.6±1.6 to 5.8±2.2 (p<0.0001). The post-infusion BPI was significantly lower in non-smokers 68.5 ±19.6 vs. smokers 80.3 ±17.2 (p=0.028) and Caucasians 69.3 ±20.3 vs. African-Americans 83.6±21.4 (p=0.027).
Conclusions: A retrospective analysis of 55 fibromyalgia patients who received IV lidocaine shows a statistically significant decrease in pain scores. A subgroup analysis shows that baseline pain scores are higher in smokers, and response to IV lidocaine is attenuated in smokers compared to non-smokers.
Published on: Apr 21, 2017 Pages: 16-22